Arcutis Strengthens Board of Directors with New Appointment of Amit Munshi and Honors Retirement of Bhaskar Chaudhuri

Core Viewpoint - Arcutis Biotherapeutics, Inc. has appointed Amit Munshi to its Board of Directors and announced the retirement of founder Bhaskar Chaudhuri, who will continue as a consultant, marking a significant leadership transition as the company aims to expand its commercial presence and pipeline in immuno-dermatology [1][2][3]. Leadership Changes - Amit Munshi brings extensive experience in biopharmaceuticals, having previously led successful transformations and strategic transactions in various companies, including a notable turnaround at Arena Pharmaceuticals that resulted in a $6.7 billion acquisition by Pfizer [2][3]. - Bhaskar Chaudhuri, a founding member and former chairman, has played a crucial role in the development of ZORYVE, which is now the top prescribed branded topical treatment across three indications [2][3]. Company Growth and Strategy - Arcutis is entering a significant growth phase, focusing on broadening the commercialization of ZORYVE and advancing its innovative pipeline to address unmet needs in dermatology [2][3]. - The company has developed a portfolio of advanced targeted topicals approved for treating major inflammatory skin diseases, leveraging its unique dermatology development platform [3]. Product Information - ZORYVE cream is indicated for the treatment of mild to moderate atopic dermatitis in pediatric patients aged 2 to 5 years and in patients aged 6 years and older, as well as for plaque psoriasis in patients aged 6 years and older [4][5]. - ZORYVE topical foam is indicated for treating plaque psoriasis of the scalp and body in patients aged 12 years and older, and for seborrheic dermatitis in patients aged 9 years and older [5]. Safety and Adverse Reactions - ZORYVE is contraindicated in patients with moderate to severe liver impairment, and the foam formulation contains flammable propellants [6]. - Common adverse reactions for ZORYVE cream and foam include upper respiratory tract infections, diarrhea, headache, and nausea, with varying incidence rates depending on the formulation and patient age group [7][8][9].